Natera, Inc. (NTRA) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Product revenues | 693.87M | FY2026-Q1 |
| Tests processed (total) | 1.01M | FY2026-Q1 |
| Net cash provided by operating activities (GAAP) | 40.2M | FY2026-Q1 |
| Licensing and other revenues | 2.78M | FY2026-Q1 |
| Loss from operations (GAAP) | 97.6M | FY2025-Q3 |
| Tests processed | 893.6K | FY2025-Q3 |
| Oncology tests | 211K | FY2025-Q3 |
| Total operating expenses (R&D + SG&A) | 482M | FY2025-Q3 |
| Tests reported | 832.9K | FY2025-Q3 |
| Tests accessioned | 879.7K | FY2025-Q3 |
| Oncology tests performed | 167.7K | FY2025-Q1 |
Back to NTRA overview · NTRA earnings · NTRA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.